{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:02:49Z","timestamp":1789398169331,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40801-026-00571-9","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:17:34Z","timestamp":1784794654000},"page":"431-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Yoshiki","family":"Hanaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Danno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Osaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo J. Philip","family":"Tharappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"571_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"571_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4610.2004.04004.x","volume":"44","author":"T Takeshima","year":"2004","unstructured":"Takeshima T, Ishizaki K, Fukuhara Y, et\u00a0al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44(1):8\u201319.","journal-title":"Headache"},{"issue":"1","key":"571_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15\u201322.","journal-title":"Cephalalgia"},{"issue":"2","key":"571_CR4","doi-asserted-by":"publisher","first-page":"033310242513206","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, Ashina M, Diener H-C, et\u00a0al. Setting higher standards for migraine prevention: a position statement of the International Headache Society. Cephalalgia. 2025;45(2):03331024251320608.","journal-title":"Cephalalgia"},{"issue":"11","key":"571_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, et\u00a0al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37(11):1945\u201355.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"571_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40120-024-00690-x","volume":"14","author":"D Danno","year":"2025","unstructured":"Danno D, Suzuki S, Takizawa T, et\u00a0al. The impact of migraine on the whole life course of patients: results from the OVERCOME (Japan) 2nd Study. Neurol Ther. 2025;14(1):335\u201356.","journal-title":"Neurol Ther."},{"issue":"1","key":"571_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, et\u00a0al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29.","journal-title":"J Headache Pain"},{"issue":"1","key":"571_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, et\u00a0al. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain. 2020;21(1):110.","journal-title":"J Headache Pain"},{"issue":"11","key":"571_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038987","volume":"10","author":"H Igarashi","year":"2020","unstructured":"Igarashi H, Ueda K, Jung S, et\u00a0al. Social burden of people with the migraine diagnosis in Japan: evidence from a population-based cross-sectional survey. BMJ Open. 2020;10(11):e038987.","journal-title":"BMJ Open"},{"issue":"1","key":"571_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, et\u00a0al. Burden of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Neurol Ther. 2022;11(1):205\u201322.","journal-title":"Neurol Ther"},{"key":"571_CR11","doi-asserted-by":"publisher","first-page":"175628642210959","DOI":"10.1177\/17562864221095902","volume":"15","author":"C Gottschalk","year":"2022","unstructured":"Gottschalk C, Buse DC, Marmura MJ, et\u00a0al. The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. Ther Adv Neurol Disord. 2022;15:17562864221095902.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"571_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","volume":"24","author":"AS Wattiez","year":"2020","unstructured":"Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020;24(2):91\u2013100.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"571_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies\u2014Successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338\u201350.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"571_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.nurpra.2019.07.009","volume":"15","author":"M Moriarty","year":"2019","unstructured":"Moriarty M, Mallick-Searle T, Barch CA, Oas K. Monoclonal antibodies to CGRP or its receptor for migraine prevention. J Nurse Pract. 2019;15(10):717-724.e1.","journal-title":"J Nurse Pract."},{"key":"571_CR15","unstructured":"Pharmaceuticals and Medical Devices Agency. List of Approved Drugs April 2004 to March 2025: Pharmaceuticals and Medical Devices Agency; 2024 [October 09, 2025]. https:\/\/www.pmda.go.jp\/files\/000274881.pdf."},{"issue":"11","key":"571_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/pm\/pnae050","volume":"25","author":"S Kikui","year":"2024","unstructured":"Kikui S, Daisuke D, Miyahara J, et\u00a0al. Effectiveness of fremanezumab treatment in patients with migraine headache. Pain Med. 2024;25(11):664\u201370.","journal-title":"Pain Med"},{"issue":"1","key":"571_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03449-3","volume":"23","author":"S Ohtani","year":"2023","unstructured":"Ohtani S, Watanabe N, Ihara K, et\u00a0al. Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study. BMC Neurol. 2023;23(1):404.","journal-title":"BMC Neurol"},{"key":"571_CR18","doi-asserted-by":"publisher","first-page":"1220285","DOI":"10.3389\/fneur.2023.1220285","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Suzuki K, Shiina T, et\u00a0al. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol. 2023;14:1220285.","journal-title":"Front Neurol"},{"issue":"4","key":"571_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26568","volume":"10","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Suzuki S, Shiina T, et\u00a0al. Real-world effectiveness of erenumab in Japanese patients with migraine. Heliyon. 2024;10(4):e26568.","journal-title":"Heliyon."},{"key":"571_CR20","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4037-24","author":"K Ihara","year":"2024","unstructured":"Ihara K, Takahashi N, Ohtani S, et\u00a0al. Real-world efficacy of erenumab on migraine-associated symptoms and patient-reported satisfaction levels: a retrospective study in Japan. Intern Med. 2024. https:\/\/doi.org\/10.2169\/internalmedicine.4037-24.","journal-title":"Intern Med"},{"issue":"1","key":"571_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, et\u00a0al. Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol. 2022;22(1):512.","journal-title":"BMC Neurol"},{"issue":"9","key":"571_CR22","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00415-023-11788-x","volume":"270","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, et\u00a0al. Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study. J Neurol. 2023;270(9):4377\u201384.","journal-title":"J Neurol"},{"issue":"1","key":"571_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12883-023-03521-y","volume":"24","author":"M Shibata","year":"2024","unstructured":"Shibata M, Fujita K, Hoshino E, et\u00a0al. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers. BMC Neurol. 2024;24(1):32.","journal-title":"BMC Neurol"},{"key":"571_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231177649","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, et\u00a0al. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan. Cephalalgia. 2023. https:\/\/doi.org\/10.1177\/03331024231177649.","journal-title":"Cephalalgia"},{"key":"571_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120811","volume":"453","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, et\u00a0al. Switching between anti-calcitonin gene-related peptide monoclonal antibodies: a comparison of monthly and quarterly dosing. J Neurol Sci. 2023;453:120811.","journal-title":"J Neurol Sci"},{"issue":"1","key":"571_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, et\u00a0al. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain. 2023;24(1):23.","journal-title":"J Headache Pain"},{"issue":"1","key":"571_CR27","volume":"15","author":"M Katsuki","year":"2023","unstructured":"Katsuki M, Kashiwagi K, Kawamura S, Koh A. Monoclonal antibodies against the calcitonin gene-related peptide and its receptor in Japanese adolescents with migraines. Cureus. 2023;15(1):e33689.","journal-title":"Cureus"},{"key":"571_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2026.125751","volume":"481","author":"S Imai","year":"2026","unstructured":"Imai S, Ihara K, Takahashi N, et\u00a0al. A 12-month observational study on the safety, efficacy on migraine-associated symptoms and satisfaction of CGRP monoclonal antibodies in Japanese patients with migraine. J Neurol Sci. 2026;481:125751.","journal-title":"J Neurol Sci"},{"key":"571_CR29","unstructured":"Ministry of Health, Labour, and Welfare. Guidelines for Promoting the Optimal Use of Galcanezumab (Genetically Recombinant) Preparations [in Japanese] Tokyo, Japan: The Japanese Headache Society; 2021 [May 08, 2025]. https:\/\/www.mhlw.go.jp\/content\/12404000\/000768564.pdf."},{"key":"571_CR30","unstructured":"Ministry of Health, Labour, and Welfare. Guidelines for Promoting the Optimal Use of Fremanezumab (Genetically Recombinant) Preparations [in Japanese] Tokyo, Japan.: The Japanese Headache Society; 2021 [May 08, 2025]. https:\/\/www.jhsnet.net\/GUIDELINE\/CGRP\/6.pdf."},{"key":"571_CR31","unstructured":"Ministry of Health, Labour, and Welfare. Guidelines for Promoting the Optimal Use of Erenumab (Genetically Recombinant) Preparations [in Japanese] Tokyo, Japan: The Japanese Headache Society; 2021 [May 08, 2025]. https:\/\/www.jhsnet.net\/GUIDELINE\/CGRP\/8.pdf."},{"key":"571_CR32","unstructured":"Headache Clinical Practice Guideline Development Committee. Clinical Practice Guideline for Headache Disorders 2021 [in Japanese]. Japanese Society of Neurology, Japanese Headache Society, Japanese Society of Neurological Therapeutics, editors. Tokyo, Japan: Igaku-Shoin; 2021."},{"key":"571_CR33","unstructured":"Pharmaceuticals : Emgality: Kyoto Encyclopedia of Genes and Genomes; 2026 [updated February 18, 2026;February 25, 2026]. https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00069230."},{"key":"571_CR34","unstructured":"Pharmaceuticals: Ajovy: Kyoto Encyclopedia of Genes and Genomes; 2026 [updated February 18, 2026;February 25, 2026]. https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00070475."},{"key":"571_CR35","unstructured":"Pharmaceuticals: Aimovig: Kyoto Encyclopedia of Genes and Genomes; 2026 [updated February 18, 2026;February 25, 2026]. https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00070783."},{"issue":"1","key":"571_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01722-5","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Iijima M, et\u00a0al. Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. J Headache Pain. 2024;25(1):19.","journal-title":"J Headache Pain"},{"issue":"12","key":"571_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315610","volume":"19","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Togo K, et\u00a0al. Clinical practice for migraine treatment and characteristics of medical facilities and physicians treating migraine: Insights from a retrospective cohort study using a Japanese claims database. PLoS ONE. 2024;19(12):e0315610.","journal-title":"PLoS ONE"},{"issue":"1","key":"571_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03600-8","volume":"24","author":"P Pozo-Rosich","year":"2015","unstructured":"Pozo-Rosich P, Carmo M, Muniz A, et\u00a0al. Migraine treatment: quo vadis? Real-world data study (2015-2022) in Spain. BMC Neurol. 2015;24(1):107.","journal-title":"BMC Neurol"},{"issue":"6","key":"571_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251341243","volume":"45","author":"S Ashina","year":"2025","unstructured":"Ashina S, Kim G, Muenzel EJ, et\u00a0al. Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: results of the OVERCOME (US) study. Cephalalgia. 2025;45(6):3331024251341243.","journal-title":"Cephalalgia"},{"key":"571_CR40","unstructured":"Calcitonin gene-related peptide (CGRP)-targeting antibodies as a first-line option for the prevention of migraine in adults: A Japanese Headache Society position statement: The Board of Directors, the Japanese Headache Society in collaboration with the Clinical Practice Guideline Committee, the Japanese Headache Society 2025 [December 12, 2025]. https:\/\/www.jhsnet.net\/english\/guideline_cgrp_en.pdf."},{"issue":"7","key":"571_CR41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1526-4610.2001.041007646.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Diamond S, et\u00a0al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646\u201357.","journal-title":"Headache"},{"issue":"3","key":"571_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1468-2982.2006.01275.x","volume":"27","author":"S Silberstein","year":"2007","unstructured":"Silberstein S, Loder E, Diamond S, et\u00a0al. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia. 2007;27(3):220\u20139.","journal-title":"Cephalalgia"},{"issue":"1","key":"571_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10194-023-01623-z","volume":"24","author":"J Pascual","year":"2023","unstructured":"Pascual J, Panni T, Dell\u2019Agnello G, et\u00a0al. Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study. J Headache Pain. 2023;24(1):88.","journal-title":"J Headache Pain"},{"issue":"2","key":"571_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Nicholson RA, Reed ML, et\u00a0al. Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache. 2022;62(2):122\u201340.","journal-title":"Headache"},{"issue":"2","key":"571_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.1999.019002107.x","volume":"19","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Kolodner K, et\u00a0al. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19(2):107\u201314.","journal-title":"Cephalalgia"},{"issue":"6 Suppl 1","key":"571_CR46","first-page":"S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20\u20138.","journal-title":"Neurology"},{"issue":"4","key":"571_CR47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1526-4610.2003.03069.x","volume":"43","author":"M Iigaya","year":"2003","unstructured":"Iigaya M, Sakai F, Kolodner KB, et\u00a0al. Reliability and validity of the Japanese Migraine Disability Assessment (MIDAS) Questionnaire. Headache. 2003;43(4):343\u201352.","journal-title":"Headache"},{"key":"571_CR48","first-page":"A89","volume":"68","author":"D Buse","year":"2007","unstructured":"Buse D, Bigal MB, Rupnow M, et\u00a0al. Development and validation of the Migraine Interictal Burden Scale (MIBS): a self-administered instrument for measuring the burden of migraine between attacks. Neurology. 2007;68:A89.","journal-title":"Neurology"},{"issue":"5","key":"571_CR49","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422\u201335.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"571_CR50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/oxfordjournals.aje.a115101","volume":"129","author":"RM Mickey","year":"1989","unstructured":"Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125\u201337.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"571_CR51","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, et\u00a0al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333\u201341.","journal-title":"Headache"},{"issue":"1","key":"571_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R, et\u00a0al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22(1):154.","journal-title":"J Headache Pain"},{"issue":"1","key":"571_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40263-025-01233-0","volume":"40","author":"LM Makita","year":"2026","unstructured":"Makita LM, Fagundes TP, Reginato PH, et\u00a0al. Estimating changes in clinical outcomes after discontinuation of anti-CGRP targeting therapy for migraine prophylaxis: a systematic review and meta-analysis. CNS Drugs. 2026;40(1):71\u201382.","journal-title":"CNS Drugs"},{"issue":"8","key":"571_CR54","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.medcli.2022.09.023","volume":"160","author":"A Castrillo","year":"2023","unstructured":"Castrillo A, Mendoza A, Caballero L, et\u00a0al. Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: a prospective study of 63 patients. Med Clin (Barc). 2023;160(8):341\u20136.","journal-title":"Med Clin (Barc)"},{"key":"571_CR55","doi-asserted-by":"crossref","unstructured":"Suzuki S, Ishii R, Danno D, et al. Patient-doctor Communication in Migraine: Results from the OVERCOME (Japan) 2nd Study. Neurol Ther. 2025;14:2695\u2013721.","DOI":"10.1007\/s40120-025-00839-2"},{"issue":"3","key":"571_CR56","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/head.14472","volume":"63","author":"M Katsuki","year":"2023","unstructured":"Katsuki M, Matsumori Y, Kawahara J, et\u00a0al. Headache education by leaflet distribution during COVID-19 vaccination and school-based on-demand e-learning: Itoigawa Geopark Headache Awareness Campaign. Headache. 2023;63(3):429\u201340.","journal-title":"Headache"},{"issue":"5","key":"571_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70447","volume":"15","author":"H Akiyama","year":"2025","unstructured":"Akiyama H, Yamano Y. Usefulness of the support video \u201ctalking picture book\u201d for overcoming hesitancy to start galcanezumab therapy. Brain Behav. 2025;15(5):e70447.","journal-title":"Brain Behav"},{"issue":"1","key":"571_CR58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40120-023-00569-3","volume":"13","author":"E Awaki","year":"2024","unstructured":"Awaki E, Takeshima T, Matsumori Y, et\u00a0al. Impact of migraine on daily life: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) study. Neurol Ther. 2024;13(1):165\u201382.","journal-title":"Neurol Ther."},{"issue":"12","key":"571_CR59","doi-asserted-by":"publisher","first-page":"813","DOI":"10.5692\/clinicalneurol.cn-001903","volume":"63","author":"T Takeshima","year":"2023","unstructured":"Takeshima T, Ooba S, Hanaoka Y, et\u00a0al. Impact of migraine on family members living with the patient: an investigation by Impact of Migraine on Partners and Adolescent Children (IMPAC) [In Japanese]. Rinsho Shinkeigaku. 2023;63(12):813\u201323.","journal-title":"Rinsho Shinkeigaku"},{"issue":"7","key":"571_CR60","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5692\/clinicalneurol.cn-001950","volume":"64","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Shibata M, Danno D, et\u00a0al. The perception gap on migraine: a survey study of the migraine patients, family members, and physicians. Rinsho Shinkeigaku. 2024;64(7):465\u201373.","journal-title":"Rinsho Shinkeigaku"},{"issue":"14","key":"571_CR61","doi-asserted-by":"publisher","first-page":"e1549","DOI":"10.1212\/WNL.0000000000200941","volume":"99","author":"N Rosendale","year":"2022","unstructured":"Rosendale N, Guterman EL, Obedin-Maliver J, et\u00a0al. Migraine, migraine disability, trauma, and discrimination in sexual and gender minority individuals. Neurology. 2022;99(14):e1549\u201359.","journal-title":"Neurology"},{"issue":"1","key":"571_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01737-y","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Ihara K, Watanabe N, et\u00a0al. CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society. J Headache Pain. 2024;25(1):39.","journal-title":"J Headache Pain"},{"key":"571_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint18010003","author":"T Tanei","year":"2025","unstructured":"Tanei T, Yamashita S, Maesawa S, et\u00a0al. Continuation, resumption, and withdrawal rates of CGRP-mAb treatment for migraine under real-world clinical conditions in which patients are free to choose own treatment. Neurol Int. 2025. https:\/\/doi.org\/10.3390\/neurolint18010003.","journal-title":"Neurol Int"},{"issue":"9","key":"571_CR64","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014759","volume":"9","author":"WK Kohl","year":"2020","unstructured":"Kohl WK, Dobos G, Cramer H. Conventional and complementary healthcare utilization among US adults with cardiovascular disease or cardiovascular risk factors: a nationally representative survey. J Am Heart Assoc. 2020;9(9):e014759.","journal-title":"J Am Heart Assoc"},{"key":"571_CR65","doi-asserted-by":"publisher","unstructured":"Ooba S, Danno D, Ishii R, et al. Characteristics and treatment patterns in people with burden of migraine: a subgroup analysis of the OVERCOME Japan 2nd study. Pain Ther. 2026. https:\/\/doi.org\/10.1007\/s40122-026-00857-4.","DOI":"10.1007\/s40122-026-00857-4"},{"key":"571_CR66","doi-asserted-by":"publisher","first-page":"1271438","DOI":"10.3389\/fpain.2023.1271438","volume":"4","author":"Y Karasawa","year":"2023","unstructured":"Karasawa Y, Yamaguchi K, Nakano S, et\u00a0al. Barriers to healthcare access in patients with chronic pain or potential migraine in Japan: a cross-sectional internet survey. Front Pain Res (Lausanne). 2023;4:1271438.","journal-title":"Front Pain Res (Lausanne)."},{"key":"571_CR67","unstructured":"Yoshida A. The Impacts of Japanese-Style Employment Systems on Women. 2022. https:\/\/www.kas.de\/documents\/287213\/16808892\/Essay_The+Impacts+of+Japanese-Style+Employment+Systems+on+Women.pdf\/2757118d-6175-b696-6faf-90afb7ccfdb9?version=1.0."},{"key":"571_CR68","unstructured":"Yamaguchi K. Japan\u2019s gender gap. Finance Dev. 2019;0056(001):A009."},{"issue":"9_suppl_6","key":"571_CR69","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1212\/WNL.58.9_suppl_6.S27","volume":"58","author":"RB Lipton","year":"2002","unstructured":"Lipton RB, Cady RK, Stewart WF, et\u00a0al. Diagnostic lessons from the spectrum study. Neurology. 2002;58(9_suppl_6):S27\u201331.","journal-title":"Neurology"},{"issue":"1","key":"571_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01614-0","volume":"24","author":"D Onan","year":"2023","unstructured":"Onan D, Younis S, Wellsgatnik WD, et\u00a0al. Debate: differences and similarities between tension-type headache and migraine. J Headache Pain. 2023;24(1):92.","journal-title":"J Headache Pain"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00571-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:04:27Z","timestamp":1789394667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00571-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00571-9","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"3 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yoshiki Hanaoka received speaker honoraria from Eli Lilly Japan K.K. Tsubasa Takizawa is a consultant\/advisor and\/or serves on an advisory board for Amgen K.K., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Teijin Pharma Limited. He received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sawai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, and UCB Japan Co. Ltd.; and grant\/funding from Eli Lilly Japan K.K., Pfizer Japan Inc., and Tsumura & Co. outside the submitted work. Ryotaro Ishii has served as a consultant for Amgen K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., and Otsuka Pharmaceutical Co., Ltd; and received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. Daisuke Danno received advisory fees from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., and Lundbeck; and honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Masayuki Hamakawa is an employee of Social Survey Research Information Co., Ltd. Social Survey Research Information Co., Ltd. performed data collection and statistical analyses in this study and was sponsored by Eli Lilly Japan K.K. Kaname Ueda, Yoshinori Tanizawa, Satoshi Osaga, and Chie Hashimoto are employees of Eli Lilly Japan K.K. and may own stock\/stock options of Eli Lilly and Company. Leo J. Philip Tharappel is an employee of Eli Lilly and Company and may own stock\/stock options of Eli Lilly and Company.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Corporation TOUKEIKAI Kitamachi Clinic ethics committee approved this study (number BGQ09531) on April 19, 2023. The study was conducted per ethical principles originating from the Declaration of Helsinki, and that were consistent with Good Pharmacoepidemiology Practices. All applicable Japanese laws and regulations were followed. All survey respondents provided electronic informed consent and agreed to participate in the study.","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are available at Eli Lilly Japan K.K on reasonable request.","order":4,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: YH, KU, YT, CH; Methodology: SO, YT, LPT; Data curation: MH; Formal analysis: YH, DD, RI, TT, MH, SO, KU, YT, LPT, CH; writing\u2014original draft: LPT; or writing\u2014review and editing: YH, TT, RI, DD, MH, KU, YT, LPT, CH. All authors reviewed and approved the submitted version and agreed to be accountable for their contributions.","order":5,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}